Immuneering Corp (IMRX)
1.39
-0.03
(-2.11%)
USD |
NASDAQ |
May 24, 16:00
1.40
+0.01
(+0.72%)
After-Hours: 20:00
Immuneering Cash from Investing (TTM): 9.717M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 9.717M |
December 31, 2023 | 7.296M |
September 30, 2023 | 12.32M |
June 30, 2023 | 35.41M |
March 31, 2023 | 48.40M |
December 31, 2022 | 41.83M |
September 30, 2022 | 10.87M |
Date | Value |
---|---|
June 30, 2022 | -41.02M |
March 31, 2022 | -63.19M |
December 31, 2021 | -75.62M |
September 30, 2021 | -52.85M |
June 30, 2021 | -0.08M |
March 31, 2021 | -0.0656M |
December 31, 2020 | -0.0534M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-75.62M
Minimum
Dec 2021
48.40M
Maximum
Mar 2023
-4.788M
Average
3.622M
Median
Cash from Investing (TTM) Benchmarks
Geron Corp | 32.62M |
SELLAS Life Sciences Group Inc | -- |
Elicio Therapeutics Inc | -0.012M |
ADMA Biologics Inc | -5.398M |
Outlook Therapeutics Inc | -- |